

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 2

Application No.	10/539,443
Filing Date	June 20, 2005
First Named Inventor	Anders Nykjaer
Art Unit	1649
Examiner	6823
Attorney Docket No.	0088562-033US0

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
-------------------	----------	---	--------------------------------	-------------------------------	--

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
-------------------	----------	--	--------------------------------	-------------------------------	--	----------------

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	1	AIRAKSINEN, <i>et al.</i> 2002. "The GDNF family: signalling. Biological functions and therapeutic value." <i>Nature Reviews - Neuroscience</i> 3:383-394.	
	2	ARSHAVSKY, Y.I. 2006. "Alzheimer's disease, brain immune privilege and memory: a hypothesis." <i>J Neural Transm</i> 113:1697-1707.	
	3	BALLABH, <i>et al.</i> 2004. "The blood-brain barrier: an overview structure, regulation, and clinical implications." <i>Neurobiology of Disease</i> 16:1-13.	
	4	BIBEL, <i>et al.</i> 1999. "Biochemical and functional interactions between the neurotrophin receptors <i>trk</i> and <i>p75^{NTR}</i> ." <i>EMBO Journal</i> 18(3):616-622.	
	5	BICKEL, Ulrich 1995. "Antibody delivery through the blood-brain barrier." <i>Advanced Drug Delivery Reviews</i> 15:53-72.	
	6	BIGNER, <i>et al.</i> 1995. "Phase I studies of treatment of malignant gliomas and neoplastic meningitis with ¹³¹ I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab) ₂ - a preliminary report." <i>Journal of Neuro-Oncology</i> 24:109-122.	
	7	CHAO, Moses V. 2003. "Neurotrophins and their receptors: a convergence point for many signalling pathways." <i>Nature Reviews - Neuroscience</i> 4:299-309.	
	8	CHEN, <i>et al.</i> 2008. "The proNGF-p75NTR-sortilin signalling complex as new target for the therapeutic treatment of Parkinson's Disease." <i>CNS Neurol Disord Drug Targets</i> 7:512-523.	
	9	DeBOER, <i>et al.</i> 2006. "Blood-brain barrier dysfunction and recovery." <i>Journal of Neural Transmission</i> 113:455-462.	
	10	DECHANT, George 2001. "Molecular interactions between neurotrophin receptors." <i>Cell Tissue Res</i> 305:229-238	
	11	FAN, <i>et al.</i> 2008. "Differential effects of pro-BDNF on sensory neurons after sciatic nerve transection in neonatal rats." <i>European Journal of Neuroscience</i> 27:2380-2390.	
	12	FRENCH, <i>et al.</i> 2003. "Protein-based therapeutic approaches targeting death receptors." <i>Cell Death and Differentiation</i> 10:117-123.	
	13	FRIDEN, <i>et al.</i> 1991. "Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier." <i>Proc. Natl. Acad. Sci. USA</i> 88:4771-4775.	
	14	LASHFORD, <i>et al.</i> 1988. "A pilot study of ¹³¹ I monoclonal antibodies in the therapy of leptomeningeal tumors." <i>Cancer</i> 61:857-868.	

Examiner Signature /Stacey Macfarlane/

Date Considered

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language translation is attached.

DWT 12981820v 10/16/05 10:30 AM REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.M./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 2 OF 2

Application No.	10/539,443
Filing Date	June 20, 2005
First Named Inventor	Anders Nykjaer
Art Unit	1649
Examiner	6823
Attorney Docket No.	0088562-033US0

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	15	LEE, <i>et al.</i> 2001. "Regulation of cell survival by secreted proneurotrophins." <i>Science</i> 194:1945-1948.	
	16	NEUWELT, Edward A. 2004. "Mechanisms of disease: the blood-brain barrier." <i>Neurosurgery</i> 54:131-142.	
	17	NYKJAER, <i>et al.</i> 2004. "Sortilin is essential for proNGF-induced neuronal cell death." <i>Nature</i> 427:843-848.	
	18	PARDRIDGE, William M. 2007. "Drug targeting to the brain." <i>Pharmaceutical Research</i> 24(9):1733-1744.	
	19	RUBENSTEIN, <i>et al.</i> 2003. "Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment." <i>Blood</i> 101(2):466-468.	
	20	RUBIN, <i>et al.</i> 1999. "The cell biology of the blood-brain barrier." <i>Annu. Rev. Neurosci.</i> 22:11-28.	
	21	TRIGUERO, <i>et al.</i> 1989. "Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein." <i>Proc. Natl. Acad. Sci. USA</i> 86:4761-4765.	
	22	VOLOSIN, <i>et al.</i> 2006. "Interaction of survival and death signaling in basal forebrain neurons: roles of neurotrophins and proneurotrophins." <i>The Journal of Neuroscience</i> 26(29):7756-7766.	
	23	WILCOCK, <i>et al.</i> 2003. "Intracranially administered anti-A β antibodies reduce β -amyloid deposition by mechanisms both independent of and associated with microglial activation." <i>The Journal of Neuroscience</i> 23(9):3745-3751.	
	24	YANO, <i>et al.</i> 2000. "Neurotrophin receptor structure and interactions." <i>Pharmaceutica Acta Helveticae</i> 74:253-260.	

Examiner Signature	/Stacey Macfarlane/	Date Considered	09/18/2009
--------------------	---------------------	-----------------	------------

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language translation is attached.

DWT 12981820v1 0088562-033US0 REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.M./